Gevo, Inc. — FY 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012. Although the request identifies 2012 Q4, this filing reports annual results and includes unaudited quarterly data. Financial amounts are in U.S. dollars unless noted.
Business context
Gevo is a development-stage renewable chemicals and biofuels company seeking to commercialize renewable isobutanol using its GIFT fermentation and separation technology, primarily by retrofitting existing ethanol plants. In May 2012, the company began startup production at its 22-million-gallon-per-year Agri-Energy facility in Minnesota, producing about 100,000 gallons. It paused production in September because output rates were below plan and management chose to optimize the process. The company said it expected to resume a limited commercial-scale campaign in 2013; this was a plan, not a demonstrated outcome.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $24.4 million | $64.5 million |
| Gross profit (loss) | $(8.0) million | $4.0 million |
| Operating expenses | $63.4 million | $48.7 million |
| Operating loss | $(71.4) million | $(44.7) million |
| Net loss | $(60.7) million | $(48.2) million |
| Cash used in operating activities | $(68.1) million | $(33.6) million |
| Cash used in investing activities | $(53.0) million | $(8.0) million |
| Cash provided by financing activities | $93.6 million | $120.6 million |
| Cash and cash equivalents at year-end | $66.7 million | $94.2 million |
Approximately $19.9 million of 2012 revenue came from ethanol and related products, down 69% from 2011; the company reported no significant ethanol shipments after startup isobutanol production began in May. Grant, research-program and other revenue was $4.5 million. Gevo recorded $6.6 million of isobutanol startup costs in cost of goods sold; quarterly disclosure identifies $7.6 million of startup costs in Q3 gross loss. The filing does not provide a clear comparable product-level isobutanol revenue figure.
Year-end current assets were $75.9 million, including cash of $66.7 million; current liabilities were $16.8 million. Total assets were $156.1 million and stockholders’ equity was $97.8 million. The company reported $25.6 million of secured debt principal and $45.0 million of convertible notes principal at year-end. The balance-sheet carrying amount of total debt was lower, reflecting the embedded-derivative valuation and debt discounts. Interest expense was $6.3 million.
Material changes versus the prior period
- Revenue fell 62%, principally because the Agri-Energy facility produced ethanol for only part of 2012 before the isobutanol startup and production pause.
- Gross results moved from a $4.0 million profit to an $8.0 million loss; operating loss widened by $26.7 million. SG&A rose 52%, including a $12.0 million increase in legal-related expenses, primarily from Butamax litigation.
- Net loss increased by $12.5 million, despite a $17.0 million non-cash gain from the decline in the fair value of embedded derivatives in the convertible notes. The gain was driven primarily by the decline in Gevo’s share price.
- Operating cash use approximately doubled, while capital spending rose to $53.0 million, largely for the Agri-Energy retrofit. Cash declined by $27.5 million during the year.
- July 2012 financing included a common-stock offering and $45.0 million of convertible notes; together, the offerings generated $98.4 million net. The stock issuance increased shares outstanding.
Outlook, risks and unusual items
- Management said year-end cash was expected to fund ongoing operations, planned capital expenditures and working capital for at least 12 months. It also expected additional capital may be needed in 2014 and stated that further production-capacity expansion would require financing. The company expected continued losses and negative operating cash flow for the foreseeable future.
- The main execution risk is whether Gevo can improve commercial production rates, reliably meet customer specifications, and produce at competitive costs. Agri-Energy retrofit costs reached approximately $56.1 million through year-end; about $49.5 million was spent on the retrofit during 2012.
- The planned Redfield, South Dakota retrofit had not begun. Gevo had incurred $0.4 million in planning costs, expected to bear retrofit costs, and said additional financing would be required to complete it.
- Commercialization depends on customer demand, binding supply arrangements, feedstock and natural-gas economics, regulatory approvals, plant retrofit performance, and the ability to sell coproducts. Under the Sasol agreement, minimum-volume obligations and potential shortfall fees apply after first commercial sales.
- Patent litigation with Butamax remained a significant contingency. The filing states that the possible loss or range of loss could not be reasonably estimated and that substantial legal costs were expected. Subsequent to year-end, March 2013 court rulings were favorable to Gevo on certain claims in an initial dispute, but Butamax said it would appeal; other litigation and trials remained pending.
- In January 2013, the board authorized a share repurchase program of up to $15 million over one year. This is a post-year-end action that would use cash also needed for development, capital spending and debt service.
- The audited financial statements received an unqualified opinion. Management reported effective disclosure controls and internal control over financial reporting at December 31, 2012. The auditor did not provide an opinion on internal-control effectiveness.
Key facts for investors to verify
- Whether 2013 isobutanol campaigns achieved sustained production rates, yields, product quality and unit economics—and whether sales were commercial rather than trial volumes.
- Current cash, operating burn, retrofit and litigation spending, and financing requirements compared with management’s stated liquidity outlook.
- Debt principal, interest, covenants, maturity and repayment restrictions, plus subsequent convertible-note conversions and resulting dilution.
- The status and financial exposure of Butamax litigation, including appeals, remaining claims and any updated loss estimates.
- Whether Sasol, Mansfield, Toray and other counterparties purchased product or met contractual commitments, and whether Gevo incurred any shortfall or refund obligations.
- Whether the $15 million repurchase authorization was used and how any repurchases affected liquidity and planned commercialization spending.